Starting in 2011, with the approval of anti-CTLA-4 treatment by the U.S. Food and Drug Administration (FDA) for advanced stage melanoma, several ICIs have been approved for cancer immunotherapy and proven effective in boosting the activation of immune responses against cancer cells [21,22]. Here, CTLA4 is linked to cancer.